Owens & Minor Q2: GAAP loss from continuing ops $83.8M; Products & Healthcare segment classified as discontinued ops

ACCENDRA HEALTH INC/VA/

2025-Q2 EPS reported -$11.60 revenue$1,355,801,000

Revenue from continuing ops $681.9M, up 3% YoY from $660.4M.
GAAP loss from continuing ops $(83.8)M vs $(6.7)M in 2Q24; adjusted net income $20.5M vs $19.3M.
Adjusted EBITDA from continuing ops $96.6M, up 6% from $91.1M.
Company in final stages of divestiture of Products & Healthcare Services segment; classified as discontinued ops.
2025 continuing ops financial outlook to be provided during 8:30 a.m. EDT earnings call.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.